<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03975101</url>
  </required_header>
  <id_info>
    <org_study_id>VSEL-knee</org_study_id>
    <nct_id>NCT03975101</nct_id>
  </id_info>
  <brief_title>Very Small Embryonic-like Stem Cells for Knee Osteoarthritis</brief_title>
  <official_title>Autologous Very Small Embryonic-like Stem Cells(VSELs) for Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Four-Leaf Clover HealthTech Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the safety and efficacy of autologous very small embryonic-like stem
      cells(VSELs) to knee osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VSELs come from the patient's peripheral blood, and will be injected in the most painful
      knee, or the worse knee on physical examination. Then follow-up the knee pain and imaging
      changes at 6 months and 1 year after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Three experimental groups were injected with different doses of VSEL, and the control group was injected with platelet-containing serum that dissolved VSEL.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The investigators screen patients with similar knee condition to ensure a small difference, and they randomized different numbers of VSELs to the patients.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of knee pain score</measure>
    <time_frame>2-4 weeks after injection</time_frame>
    <description>Pain assessment by visual analogue score (VAS). 0 point: no pain; 1-3 points: there is a slight pain that can be tolerated; 4-6 points: the patient has pain and affects sleep, and can still bear it; 7-10 points: the patient has progressively strong pain, pain is unbearable, affecting appetite and sleep</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of knee pain score</measure>
    <time_frame>6 months after injection</time_frame>
    <description>Pain assessment by visual analogue score (VAS). 0 point: no pain; 1-3 points: there is a slight pain that can be tolerated; 4-6 points: the patient has pain and affects sleep, and can still bear it; 7-10 points: the patient has progressively strong pain, pain is unbearable, affecting appetite and sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging changes in the knee joint</measure>
    <time_frame>6 months after injection</time_frame>
    <description>Magnetic resonance image (MRI) examination of the smoothness of the knee joint surface, ligament, soft tissue and meniscus damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of knee pain score</measure>
    <time_frame>12 months after injection</time_frame>
    <description>Pain assessment by visual analogue score (VAS). 0 point: no pain; 1-3 points: there is a slight pain that can be tolerated; 4-6 points: the patient has pain and affects sleep, and can still bear it; 7-10 points: the patient has progressively strong pain, pain is unbearable, affecting appetite and sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging changes in the knee joint</measure>
    <time_frame>12 months after injection</time_frame>
    <description>MRI examination of the smoothness of the knee joint surface, ligament, soft tissue and meniscus damage</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stem Cell Transplant Complications</condition>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>VSEL Max</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A mean volume of 5.5 mL platelet-rich plasma containing approximately 120,000 cells were prepared and injected into the selected knee of the patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VSEL Medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A mean volume of 5.5 mL platelet-rich plasma containing approximately 90,000 cells were prepared and injected into the selected knee of the patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VSEL Mini</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A mean volume of 5.5 mL platelet-rich plasma containing approximately 60,000 cells were prepared and injected into the selected knee of the patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A mean volume of 5.5 mL platelet-rich plasma containing no VSELs injected into the selected knee of the patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>very small embryonic-like stem cell</intervention_name>
    <description>Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation</description>
    <arm_group_label>VSEL Max</arm_group_label>
    <arm_group_label>VSEL Medium</arm_group_label>
    <arm_group_label>VSEL Mini</arm_group_label>
    <other_name>VSEL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients had moderate to severe osteoarthritis of both knees.

          -  Those had mechanical pain of knee joints, which was aggravated by walking or stair
             climbing.

          -  Those complained of gelling pain of knee joint.

          -  Those have crepitus and limitation of the joint range of motion with joint bony
             hypertrophy on physical examination, X-rays showed narrowing of joint space and
             osteophyte formation

        Exclusion Criteria:

          -  Diabetic foot and patients with obvious edema in the legs caused by various causes

          -  Blood disease patients, thrombocytopenia or dysfunction, hypofibrinemia or
             anticoagulant therapy, long-term use of aspirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jibing Chen, PhD</last_name>
    <phone>+86-18903068207</phone>
    <email>jibingchen398@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biological treatment center in Fuda cancer hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Jibing, PhD</last_name>
      <phone>+86-18903068207</phone>
      <email>jibingchen398@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>May 24, 2020</last_update_submitted>
  <last_update_submitted_qc>May 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

